Analyst upgrades, downgrades and initiations: ABMD, TI, DKS, SCHW ...


Analyst upgrades:
  • Jefferies upgraded Abiomed (NASDAQ: ABMD) to Hold from Underperform on valuation as it believes concerns over the company's Impella heart pump are priced in at current levels. The firm lowered its target price to $7 from $8.
  • Suntrust upgraded Somanetics (NASDAQ: SMTS) to Neutral from Reduce. The firm believes most of the risk is out of Somanetics shares and that the Q1 report could be a positive catalyst.
  • Banc of America/Merrill upgraded shares of Telecom Italia (NYSE: TI) to Buy from Neutral on valuation and believes the company's revenue trends are improving.
  • China Petroleum & Chemical (NYSE: SNP) was raised to Buy from Neutral at UBS.
  • Hexcel (NYSE: HXL) and Johnson Controls (NYSE: JCI) were upgraded to Buy from Neutral at Goldman.
Analyst downgrades:
  • Jefferies downgraded shares of Energy XXI (NASDAQ: EXXI) to Underperform from Buy and Parallel Petroleum (NASDAQ: PLLL) to Hold from Buy to reflect the low commodity prices and believes the company must preserve liquidity. It lowered its price target on Energy XXI to 30c from $1 and lowered its target on Parallel Petroleum to $1 from $12.
  • Merriman downgraded Xoma (NASA: XOMA) to Neutral from Buy to reflect financial distractions after the company's independent accountants placed a going concern on it.
  • Piper downgraded Metabolix (NASDAQ: MBLX) to Neutral from Buy after the company announced another delay in the start-up of its first commercial-scale production facility.
  • Dick's Sporting Goods (NYSE: DKS) was cut to Neutral from Buy at Goldman.
  • American Tower (NYSE: AMT) was downgraded at Morgan Stanley to Equal Weight from Overweight.
  • Sunpower (NASDAQ: SPWRA) was downgraded to Underweight from Overweight at JP Morgan.
Analyst initiations:
  • Thomas Weisel said Supertex (NASDAQ: SUPX) faces near-term challenges from high DOI, inventory correction in medical, and lack of visibility in LED driver ramp. Shares were initiated with a Market Weight rating and $20 target.
  • Citigroup believes Charles Schwab (NASDAQ: SCHW) is the preeminent discount broking franchise and feels 2009's challenges are already priced into shares. Shares were assumed with a Buy rating and $16 target.
  • JMP Securities initiated Sequenom (NASDAQ: SQNM) with an Outperform rating and $25 target. The firm believes Sequenom is poised to become the leader in non-invasive prenatal diagnostics with its soon-to-be-launched SEQureDx test.
  • Allergan (NYSE: AGN) was initiated at Piper Jaffray with a Buy rating and $48 target.
  • Data Domain (NASDAQ: DDUP) was assumed with a Neutral rating at Merriman.
  • American Capital (NASDAQ: AGNC) was started at Keefe Bruyette with a Market Perform rating and $17.50 target.
Symbol Lookup
IndexesChangePrice
DJIA-134.1512,756.31
NASDAQ-24.852,902.38
S&P 500-12.111,339.84

Last updated: February 10, 2012: 02:24 PM

Hot Stocks

General Electric

18.82-0.31(-1.62)

Alcoa

10.25-0.39(-3.67)

Apple Inc

492.95-0.22(-0.04)

Google Inc 'A'

605.36-6.10(-1.00)

Bank of America

8.065-0.115(-1.41)

Wal-Mart Stores

61.48-0.48(-0.77)

Exxon Mobil Corp

83.51-1.37(-1.61)

Ford

12.40-0.29(-2.29)

Citigroup

32.87-0.79(-2.35)

IBM

191.59-1.54(-0.80)

Yahoo

16.20+0.20(+1.25)

Starbucks

48.64-0.56(-1.14)

Microsoft

30.54-0.23(-0.75)

Home Depot

45.06-0.21(-0.46)

DailyFinance Headlines

Benzinga Headlines

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

DailyFinance BlackBerry App

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

BioHealth Investor Headlines

Page Loaded in 1328901858801 ms.